Back to Journals » Cancer Management and Research » Volume 11

MicroRNA-371-3 cluster as biomarkers for the diagnosis and prognosis of cancers

Authors Pan B, He B, Xu X, Liu X, Xu T, Xu M, Chen X, Zeng K, Lin K, Hu X, Sun L, Pan Y, Sun H, Wang S

Received 14 October 2018

Accepted for publication 23 April 2019

Published 13 June 2019 Volume 2019:11 Pages 5437—5457


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Rituraj Purohit

Bei Pan,1,* Bangshun He,1,* Xueni Xu,1,2 Xiangxiang Liu,1 Tao Xu,1 Mu Xu,1 Xiaoxiang Chen,1,2 Kaixuan Zeng,1,2 Kang Lin,3 Xiuxiu Hu,1,2 Li Sun,4 Yuqin Pan,1 Huiling Sun,1 Shukui Wang,1,3,5

1General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People’s Republic of China; 2School of Medicine, Southeast University, Nanjing 210009, People’s Republic of China; 3Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People’s Republic of China; 4Department of Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, People’s Republic of China; 5Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People’s Republic of China

*These authors contributed equally to this work

Purpose: To date, increasing evidences have demonstrated that the aberrant expression of miR-371–3 cluster has been verified in various cancers and could be potentially used as a biomarker for tumor diagnosis and prognosis. To explore the role of miR-371–3 cluster in tumor diagnosis and prognosis, we conducted this study based on the published data.
Methods: We searched electronic databases (PubMed, EMBASE and Web of Science databases) (Jan 1, 2007 to Jun 1, 2018). The pooled sensitivity, specificity and area under the curve (AUC) of summary receiver operator characteristic (SROC) curve were used for diagnostic values, meanwhile the pooled hazard ration (HR) and 95% CI were used to explore the prognosis capacity of miR-372 and miR-373. In addition, the publication bias of the enrolled studies was tested and a sensitivity analysis of each study was performed to evaluate the stability of the pooled result.
Results: A total of eleven eligible studies containing six eligible studies containing 870 participants for diagnosis and 1218 cancer cases for prognosis were selected for this study. For diagnosis, the pooled results revealed that the miR-371 (sensitivity: 0.85, specificity: 0.92, AUC: 0.92) and miR-373 (sensitivity: 0.81, specificity: 0.93, AUC: 0.93) could be used as diagnostic biomarkers. For prognosis, we observed that elevated miR-372 indicated poor prognosis (HR=2.31, 95% CI: 1.04–5.14), especially in the cutoff value subgroup of median (HR=2.62, 95% CI: 1.54–4.46). In addition, pooled results showed that expression of miR-373 was not related to prognosis because of the significant heterogeneity, and the high miR-373 expression presented favorable prognosis in Asians (HR=0.34, 95% CI: 0.23–0.50) after omitting the study of heterogeneity origin.
Conclusion: The current studies demonstrated that miR-371 and miR-373 could be predictive tumor diagnostic biomarkers and the expression of miR-372 and miR-373 may indicate prognosis of cancer patients.

Keywords: cancer, miR-371, miR-372, miR-373, diagnosis, prognosis, biomarkers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]